ArticleiScience2026
A high-throughput co-culture CRISPR array for rapid fitness hypothesis testing and growth engineering in CHO cells.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell growth and fitness shape mammalian biomanufacturing performance, but subtle genetic effects are difficult to resolve with conventional growth assays. We developed a high-throughput competitive co-culture CRISPR array in Chinese hamster ovary (CHO) suspension cells that pairs a CRISPR-competent population with a CRISPR-inactive green fluorescent protein (GFP) reference pool and tracks GFP-ratio dynamics by flow cytometry. Guided by a prior genome-wide CRISPR screen, we tested 235 single-gene knockouts and 155 multiplex gene sets across seven batches and >100 days of cultivation. The assay detected expected lethal and growth-inhibitory perturbations and identified 28 growth-enhancing knockouts or gene sets that are poorly resolved by viable-cell-concentration measurements. Slope-based modeling converted GFP dynamics into inferred growth rate changes, and combinatorial exclusion with bulk transcriptomics linked multiplex phenotypes to candidate driver genes. The approach enables scalable fitness hypothesis testing and prioritization of CHO growth-engineering targets for downstream host-cell development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.